Jazz Pharmaceuticals Sets Aside $57 Million to Settle DOJ Probe

Jazz Pharmaceuticals Plc reached a tentative agreement with the Justice Department to settle a probe over its donations to charities that help people afford drugs, part of a long-running U.S. investigation into drugmaker ties to such groups.

In a securities filing on May 8, the maker of the costly narcolepsy drug Xyrem said it reached an agreement in principle in April for a civil settlement and has set aside $57 million to resolve the probe. The company had previously received multiple subpoenas from the Justice Department over its charitable donations.

“We cannot provide assurances that our efforts to reach a ...